

NEW PRONTO RECHARGEABLE, VAPOUR RELEASE TECHNOLOGY REGISTERED WITH US FDA AND AUSTRALIAN TGA

HIGHLIGHTS:

- **New Pronto™ range of dual action, rechargeable vapour release products to go on sale in the second half of 2019.**
- **Pronto™ range comes in two formulation variants - Pronto™ Sleep and Pronto™ Clear - addressing unmet needs in the US\$28bn global sleep aid market* and US\$34bn global nasal congestion, cough, cold and allergy market#.**
- **Both Pronto Sleep and Pronto Clear have been successfully registered with the USA FDA and Australian TGA as Class 1 devices.**

May 17, 2019. Melbourne. Rhinomed (ASX:RNO), a leader in airway technology, and the developers of Mute™, is pleased to confirm that its revolutionary new Pronto™ rechargeable, dual action, vapour release technology has been registered with both the US FDA and the Australian TGA as a class I medical device.

Regulatory clearance in two critical markets

In the USA, Rhinomed has now completed registration of Pronto covering both variants - Pronto Sleep and Pronto Clear - as a Class I medical device with the US FDA under Device Classification Name: Dilator, Nasal, Product Code: LWF Regulation Number: 874.3900

In Australia, Rhinomed can confirm the classification of Pronto as a Class I medical device for the ARTGA under Rhinomed's existing TGA listing under the same product category as its Mute and Turbine products and the same GMDN Code: 47607 Nasal Breathing aid, internal, reusable.

Revolutionary new Pronto™ technology suite

Based on the company's existing BreatheAssist™ nasal dilator technology (Mute™ and Turbine™), the new Pronto™ OTC range includes the novel Airstream™ release system that allows a continuous release of an essential oil blend into the nasal airstream over a set period of time. By combining this new vapour release technology with the Mute's stenting action, Rhinomed provides users with a unique dual action device that not only improves nasal airflow but also delivers a soothing blend of pure essential oils traditionally known to help clear a stuffy nose or to help you sleep better naturally.

Pronto also includes a novel recharging and storage case that allows Pronto to be recharged before each use. When Pronto is stored in its case in the recharge position, the Pronto device is replenished with the essential oil formulation so it is ready for use again.

RHINOMED

MAKE EVERY BREATH COUNT



Rhinomed is completing production and will be shipping the new products at the end of May. Rhinomed can confirm that both Pronto products will initially be sold online and through select retail partners.

This unique and patented technology could have a broad range of applications and investigations into how it may be tailored to other formulations and specific drug delivery profiles such as low dose/long release or high dose/fast acting, are underway.

For more information about Rhinomed's exciting technology, please visit www.rhinomed.global

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Warrick Lace NWR Communications +61(0) 404 656 408 warrick@nwrcommunications.com.au

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

** Top 6 Things to Know About the \$28 Billion Sleep Market. Market research.com 2019*
Trends in Cough, Cold and Allergy (Hay Fever) Remedies Euromonitor 2015

For personal use only